SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European ...

Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and highly aggressive form of mature T-cell leukemiaNEW YORK, Oct. 13, 2025 (GLOBE ...
Morningstar

MEDiC Life Sciences Acquires Clinical-Stage Oncology Program, Validating SLS Biomarker Platform

MEDiC Life Sciences, a leader in next-generation functional genomics in 3D cancer models, today announced the acquisition of a clinical-stage therapeutic program. This landmark acquisition is the ...
Hotelier Middle East

From leadership moves to The Red Sea milestones: Saudi’s biggest stories of the week

New openings, artistic collaborations and executive appointments shape Saudi’s hospitality stories this week. From leadership ...

Once unthinkable, NASA and Lockheed now consider launching Orion on other rockets

The Orion spacecraft and Space Launch System rocket have been attached at the hip for the better part of two decades. The big ...
The Voice

Research highlights need to tackle racism in outdoor spaces

While participation rates across activities like walking, running, and cycling are broadly similar between people of colour ...
Stocktwits on MSN

SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment

SELLAS Life Sciences Group (SLS) announced on Monday that preclinical data support its SLS009 as a monotherapy or in combination with Venetoclax for treating a rare and highly aggressive form of ...